Peter J.:
If you have anything concrete to contribute, please do it. Otherwise, leave joke for somebody else, or some other public SUGN board. In the other words, with that lips you can kiss...(well, I think that you got the point).
For instance, tell as how you fill about recent financing and why? Or, why is SUGN going against metastatic colon cancer (advance and naive pts), not all and mixed pts population? What this have to do with EU SU5416 metastatic solid tumor cancer trial, which Rosen *forgot* to mentioned. Ah yes, it is not conduced at JJC.
Also, why this sentence in Reuter news:
<<The angiogenesis inhibitors seem to be non-toxic in adults, although one -- thalidomide -- is known to cause severe birth defects.>>
Are they afraid of Thalidomide?
First, all angiogenesis inhibitors are not non-toxic, and second, if one exclude thalidomide embrionic toxicity (btw, isn't embrionic development very, very close to cancerogenesis?) its toxic profile are not that different than others, as I had read. However SU5416 is far less toxic than some other anti-angiogenesis drugs.
Have a nice night!
Miljenko
|
